The first patient meeting of 2025 will take place in Manchester on the 28th of March. To express an interest in attending and to keep abreast of developments email meetings@gistcancer.org.uk
All News Articles
Help improve NHS sarcoma services
Sarcoma UK is gathering views on NHS sarcoma care across the UK to help us to better understand how well the NHS is doing and what it needs to improve. […]
October Patient/Carer Meeting – London
The next Patient/Carer meeting will be held in London on 4th October 2024. You can find out how to register here.
UK clinical practice guidelines – June 2024
We are delighted to announce that the National GIST guidelines have been updated by the British Sarcoma Group GIST specialists and published on 4th June 2024. A copy of the […]
GIST Cancer UK and Sarcoma UK announce joint research funding
Sarcoma UK and GIST Cancer UK are teaming up to spend £164,182 on new GIST research, to understand these cancers better, and lay the foundations for the development of better […]
Newsletter – Spring 2024
Welcome to the third edition of our Newsletter which has been designed to be as informative as possible to everyone affected by GIST Cancer. It contains information about our most […]
Phase 2 Trial – Avelumab Plus Regorafenib
Combination treatment with avelumab and regorafenib has shown activity in patients with relapsed/refractory gastrointestinal stromal tumors (GIST), according to research presented at the European Society for Medical Oncology (ESMO) Congress […]
Newsletter – Autumn 2023
Welcome to the second edition of our Newsletter which has been designed to be as informative as possible to everyone affected by GIST Cancer. It contains information about our most […]
Leeds Sessions 2023
Videos of the sessions at the October 2023 Patient Carer meeting held in Leeds are now available on the Patient Meetings 2023 section of this site.
Ripretinib vs Sunitinib 2023
The outcome of the recent Intrigue study which compared the effectiveness and side effects associated with these drugs can be found here.